SCHEMBL7247264

SCHEMBL7247264

O=C(O)N[C@H](Cc1cncs1)C(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1

nearest known ligand 0.60

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HRH2 P25021 20/20 0.60
HRH1 P35367 20/20 0.60
HRH3 Q9Y5N1 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7244753 0.87 HRH2 (0.64) HRH2HRH1HRH3
SCHEMBL7246294 0.84 HRH2 (0.83) HRH2HRH1HRH3
SCHEMBL7251251 0.83 HRH2 (0.72) HRH2HRH1HRH3
SCHEMBL7251257 0.83 HRH2 (0.72) HRH2HRH1HRH3
SCHEMBL7979547 0.82 HRH2 (0.57) HRH2HRH1HRH3
SCHEMBL7245943 0.82 HRH2 (0.75) HRH2HRH1HRH3
SCHEMBL7248662 0.81 HRH2 (0.63) HRH2HRH1HRH3
SCHEMBL7982560 0.81 HRH2 (0.75) HRH2HRH1HRH3
SCHEMBL7245920 0.81 HRH2 (0.75) HRH2HRH1HRH3
SCHEMBL7244430 0.80 HRH2 (0.68) HRH2HRH1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6559140-B2 Cyclic and bicyclic diamino histamine-3 receptor antagonists ABBOTT LABORATORIES 2003-05-06 US claimed
US-20010049367-A1 Cyclic and bicyclic diamino histamine-3 receptor antagonists ABBVIE INC. 2001-12-06 US claimed
US-6559140-B2 Cyclic and bicyclic diamino histamine-3 receptor antagonists ABBOTT LABORATORIES 2003-05-06 US disclosed
US-20010049367-A1 Cyclic and bicyclic diamino histamine-3 receptor antagonists ABBVIE INC. 2001-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049367-A1 Cyclic and bicyclic diamino histamine-3 receptor antagonists HRH4, HRH2, HRH3 HRH2 2/4885HRH1 4/4885HRH3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.